Max Robotics — Global Service Robot Directory + US Certification

About

Rachel Brody is a rising leader in prostate cancer research, whose work bridges urologic pathology and clinical oncology to redefine how aggressive disease is detected and understood. Her key research areas include the tumor microenvironment, pelvic inflammation, and advanced imaging techniques for prostate cancer. In her seminal 2022 study, Brody was the first to systematically evaluate the link between incidental pelvic inflammation and aggressive prostate cancer biology, demonstrating that inflammatory changes in the prostate microenvironment are associated with more aggressive tumor phenotypes and poorer clinical outcomes after radical prostatectomy—a finding that has already garnered 15 citations and opened a new avenue for risk stratification. Building on this, her 2023 work on microultrasound for detecting the index lesion—the single precursor cell driving metastasis—showed that this high-resolution imaging modality can effectively identify the dominant tumor focus, offering a more precise, cost-effective alternative to multiparametric MRI. With 13 citations in just over a year, this study positions her at the forefront of image-guided diagnostics. Brody’s contributions are shaping a future where inflammation and microimaging converge to personalize prostate cancer management.